SCHEMBL2007365

SCHEMBL2007365

COc1ccc(S(=O)(=O)N(C)CCN(C)c2nc(Cc3ccc(C)cc3)ns2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
TSHR P16473 1/20 0.45
HTT P42858 1/20 0.45
RECQL P46063 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
GAA P10253 1/20 0.42
ALDH1A1 P00352 3/20 0.41
MAPT P10636 4/20 0.40
PKM P14618 1/20 0.40
GBA1 P04062 1/20 0.40
MAPK1 P28482 2/20 0.40
KMT2A Q03164 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
PTGER1 P34995 3/20 0.39
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
EGFR P00533 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1020162 0.96 NOS2 (0.40) LMNATSHRHTTRECQLSMN1; SMN2
SCHEMBL2012105 0.91 TAS2R14 (0.41) LMNASMN1; SMN2ALDH1A1MAPTEGFR
SCHEMBL2003100 0.91 CNR2 (0.41) SMN1; SMN2ALDH1A1MAPTCNR2PTGER1
SCHEMBL1022400 0.91 ALDH1A1 (0.40) LMNATSHRHTTALDH1A1GBA1
SCHEMBL2005838 0.89 MAPT (0.46) LMNATSHRHTTRECQLSMN1; SMN2
SCHEMBL1019577 0.87 ALDH1A1 (0.38) LMNATSHRHTTRECQLSMN1; SMN2
SCHEMBL1020526 0.86 BMP1 (0.41) LMNASMN1; SMN2GAAALDH1A1MAPT
SCHEMBL1020919 0.85 ALDH1A1 (0.51) LMNASMN1; SMN2GAAALDH1A1MAPT
SCHEMBL2008108 0.84 TAS2R14 (0.40) LMNATSHRHTTRECQLSMN1; SMN2
SCHEMBL2002634 0.84 MGAT3 (0.42) SMN1; SMN2GAAALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US claimed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US claimed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP LMNA 1913/4885TSHR 3125/4885HTT 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.